Product Description: Feprazone (DA2370; Prenazone), an analogue of Phenylbutazone (HY-B0230), is a nonsteroidal anti-inflammatory agent with analgesic and antipyretic activities. Feprazone acts by inhibiting the activity of cyclooxygenase (COX)-2. Feprazone ameliorates free fatty acid (FFA)-induced oxidative stress by reducing the production of mitochondrial reactive oxygen species (ROS). Feprazone can decrease the expression of MMP-2 and MMP-9. Besides, Feprazone can suppress adipogenesis and increase lipolysis in differentiating 3 T3-L1 cells. Feprazone also can be used to research atherosclerosis and obesity[1][2][3].
Applications: COVID-19-immunoregulation
Formula: C20H20N2O2
References: [1]Song M, et al. Feprazone Prevents Free Fatty Acid (FFA)-Induced Endothelial Inflammation by Mitigating the Activation of the TLR4/MyD88/NF-κB Pathway. ACS Omega. 2021 Feb 9;6(7):4850-4856./[2]Fletcher MR, et al. Feprazone, a new anti-inflammatory agent. Studies of potency and gastrointestinal tolerance. Ann Rheum Dis. 1975 Apr;34(2):190-4./[3]Che L, et al. Feprazone Displays Antiadipogenesis and Antiobesity Capacities in in Vitro 3 T3-L1 Cells and in Vivo Mice. ACS Omega. 2021 Mar 7;6(10):6674-6680.
CAS Number: 30748-29-9
Molecular Weight: 320.39
Compound Purity: 99.88
Research Area: Inflammation/Immunology
Solubility: DMSO : 12.5 mg/mL (ultrasonic;warming;heat to 60°C)
Target: COX;MMP;Reactive Oxygen Species